MediciNova (MNOV) News Today $1.31 +0.01 (+0.77%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 10:29 PM | finance.yahoo.comMediciNova, Inc. (MNOV)July 26 at 1:27 AM | americanbankingnews.comMediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.comJuly 19, 2024 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.comJuly 18, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Now Covered by StockNews.comStockNews.com assumed coverage on shares of MediciNova in a research report on Thursday. They issued a "hold" rating for the company.July 10, 2024 | marketbeat.comStockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV)StockNews.com assumed coverage on MediciNova in a research note on Wednesday. They issued a "hold" rating on the stock.June 29, 2024 | marketbeat.comMediciNova, Inc. (NASDAQ:MNOV) Short Interest UpdateMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 110,700 shares, a decline of 18.4% from the May 31st total of 135,600 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 34,200 shares, the days-to-cover ratio is presently 3.2 days.June 24, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Receives New Coverage from Analysts at StockNews.comStockNews.com began coverage on shares of MediciNova in a report on Monday. They set a "hold" rating on the stock.June 20, 2024 | globenewswire.comMediciNova Chief Business Officer David H. Crean, Ph.D.June 5, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid CancerJune 3, 2024 | globenewswire.comMediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024May 30, 2024 | marketbeat.comShort Interest in MediciNova, Inc. (NASDAQ:MNOV) Decreases By 25.5%MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 158,600 shares, a decline of 25.5% from the April 30th total of 212,900 shares. Approximately 0.3% of the company's stock are short sold. Based on an average daily volume of 35,700 shares, the short-interest ratio is presently 4.4 days.May 28, 2024 | globenewswire.comMediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic ConditionsMay 23, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.comStockNews.com began coverage on MediciNova in a research report on Thursday. They set a "hold" rating on the stock.May 20, 2024 | stockhouse.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 20, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 14, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress SyndromeMay 7, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)May 7, 2024 | globenewswire.comMediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)April 30, 2024 | finance.yahoo.comMediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years agoApril 27, 2024 | marketbeat.comMediciNova, Inc. (NASDAQ:MNOV) Short Interest Down 26.0% in AprilMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 247,000 shares, a decrease of 26.0% from the March 31st total of 333,600 shares. Based on an average daily volume of 49,400 shares, the days-to-cover ratio is presently 5.0 days. Currently, 0.5% of the shares of the company are sold short.April 2, 2024 | globenewswire.comMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)March 27, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 27, 2024 | msn.comPre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…March 27, 2024 | marketwatch.comMediciNova Gets Patent in Japan for Multiple Sclerosis-Related TreatmentMarch 27, 2024 | tmcnet.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 26, 2024 | globenewswire.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 20, 2024 | globenewswire.comMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis SocietyMarch 20, 2024 | finance.yahoo.comCompanies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In GrowthMarch 12, 2024 | globenewswire.comMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of ToxicologyFebruary 29, 2024 | finance.yahoo.comMNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…February 28, 2024 | money.usnews.comMedicinova IncJanuary 17, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaJanuary 17, 2024 | finance.yahoo.comMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaDecember 21, 2023 | finance.yahoo.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of ToxicologyDecember 6, 2023 | markets.businessinsider.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeDecember 6, 2023 | finance.yahoo.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeNovember 27, 2023 | finance.yahoo.comMNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…November 22, 2023 | finance.yahoo.comThe past five years for MediciNova (NASDAQ:MNOV) investors has not been profitableNovember 20, 2023 | msn.comWhy Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?November 19, 2023 | finance.yahoo.comMediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-OncologyOctober 28, 2023 | benzinga.comMediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaOctober 27, 2023 | finance.yahoo.comMediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaOctober 12, 2023 | finance.yahoo.comWe're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash WiselyOctober 10, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in CanadaOctober 5, 2023 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives Gene Therapy Milestone PaymentOctober 4, 2023 | finance.yahoo.comMediciNova Receives Gene Therapy Milestone PaymentSeptember 29, 2023 | finance.yahoo.comMNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model…September 28, 2023 | msn.comMediciNova gains after nonclinical data for lead asset in lung injurySeptember 27, 2023 | finance.yahoo.comMediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryAugust 21, 2023 | finance.yahoo.comMNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury… Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address How to build the ultimate dividend portfolio (Ad)There’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again. Click here and I’ll show you how to build the ultimate dividend portfolio. MNOV Media Mentions By Week MNOV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNOV News Sentiment▼0.830.62▲Average Medical News Sentiment MNOV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNOV Articles This Week▼31▲MNOV Articles Average Week Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HOOK News Today KZR News Today NXTC News Today VSTM News Today VYNE News Today ALDX News Today IMMP News Today EPIX News Today ACRV News Today CDXC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNOV) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.